Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1990 1
1993 1
1994 1
1996 1
1998 1
1999 2
2000 2
2001 2
2002 3
2003 1
2004 2
2005 1
2006 3
2007 1
2008 4
2009 3
2010 3
2011 6
2012 4
2013 14
2014 12
2015 5
2016 1
2017 9
2018 13
2019 9
2020 12
2021 16
2022 11
2023 21
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Therapies for Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.
Shah VA, Gonzalez LF, Suarez JI. Shah VA, et al. Among authors: gonzalez lf. Neurocrit Care. 2023 Aug;39(1):36-50. doi: 10.1007/s12028-023-01747-9. Epub 2023 May 25. Neurocrit Care. 2023. PMID: 37231236 Review.
The existing literature on DCI rescue therapies is limited by small sample sizes, significant variability in patient populations, lack of standardized methodology, variable definitions of DCI, poorly reported outcomes, lack of long-term functional, cognitive, and patient-c …
The existing literature on DCI rescue therapies is limited by small sample sizes, significant variability in patient populations, lack of st …
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study.
McCrea MA, Giacino JT, Barber J, Temkin NR, Nelson LD, Levin HS, Dikmen S, Stein M, Bodien YG, Boase K, Taylor SR, Vassar M, Mukherjee P, Robertson C, Diaz-Arrastia R, Okonkwo DO, Markowitz AJ, Manley GT; TRACK-TBI Investigators; Adeoye O, Badjatia N, Bullock MR, Chesnut R, Corrigan JD, Crawford K, Duhaime AC, Ellenbogen R, Feeser VR, Ferguson AR, Foreman B, Gardner R, Gaudette E, Goldman D, Gonzalez L, Gopinath S, Gullapalli R, Hemphill JC, Hotz G, Jain S, Keene CD, Korley FK, Kramer J, Kreitzer N, Lindsell C, Machamer J, Madden C, Martin A, McAllister T, Merchant R, Ngwenya LB, Noel F, Nolan A, Palacios E, Perl D, Puccio A, Rabinowitz M, Rosand J, Sander A, Satris G, Schnyer D, Seabury S, Sherer M, Toga A, Valadka A, Wang K, Yue JK, Yuh E, Zafonte R. McCrea MA, et al. Among authors: gonzalez l. JAMA Neurol. 2021 Aug 1;78(8):982-992. doi: 10.1001/jamaneurol.2021.2043. JAMA Neurol. 2021. PMID: 34228047 Free PMC article.
CONCLUSIONS AND RELEVANCE: In this study, patients with msTBI frequently demonstrated major functional gains, including recovery of independence, between 2 weeks and 12 months postinjury. Severe impairment in the short term did not portend poor outcomes in a substantial mi …
CONCLUSIONS AND RELEVANCE: In this study, patients with msTBI frequently demonstrated major functional gains, including recovery of independ …
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
BACKGROUND: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits …
BACKGROUND: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin …
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analys …
BACKGROUND: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiova …
Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts.
Alemany S, Avella-García C, Liew Z, García-Esteban R, Inoue K, Cadman T, López-Vicente M, González L, Riaño Galán I, Andiarena A, Casas M, Margetaki K, Strandberg-Larsen K, Lawlor DA, El Marroun H, Tiemeier H, Iñiguez C, Tardón A, Santa-Marina L, Júlvez J, Porta D, Chatzi L, Sunyer J. Alemany S, et al. Among authors: gonzalez l. Eur J Epidemiol. 2021 Oct;36(10):993-1004. doi: 10.1007/s10654-021-00754-4. Epub 2021 May 28. Eur J Epidemiol. 2021. PMID: 34046850 Free PMC article.
We aimed to study this association in a collaborative study of six European population-based birth/child cohorts. A total of 73,881 mother-child pairs were included in the study. ...These results replicate previous work and support providing clear information to pregnant w …
We aimed to study this association in a collaborative study of six European population-based birth/child cohorts. A total of 73,881 m …
The antioxidant l-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria.
Mayayo-Vallverdú C, López de Heredia M, Prat E, González L, Espino Guarch M, Vilches C, Muñoz L, Asensi MA, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, Garcia-Roves PM, Pallardó FV, Nunes V. Mayayo-Vallverdú C, et al. Among authors: gonzalez l. Redox Biol. 2023 Aug;64:102801. doi: 10.1016/j.redox.2023.102801. Epub 2023 Jun 26. Redox Biol. 2023. PMID: 37418888 Free PMC article.
In this study, the antioxidant l-Ergothioneine was evaluated, at two different doses, as a preventive and long-term treatment for cystinuria in the Slc7a9(-/-) mouse model. l-Ergothioneine treatments decreased the rate of stone formation by more than 60% and delayed its on …
In this study, the antioxidant l-Ergothioneine was evaluated, at two different doses, as a preventive and long-term treatment for cys …
Flow-diversion panacea or poison?
Zanaty M, Chalouhi N, Tjoumakaris SI, Rosenwasser RH, Gonzalez LF, Jabbour P. Zanaty M, et al. Among authors: gonzalez lf. Front Neurol. 2014 Feb 28;5:21. doi: 10.3389/fneur.2014.00021. eCollection 2014. Front Neurol. 2014. PMID: 24592254 Free PMC article. Review.
The most widely used devices are the pipeline embolization device (PED), the SILK flow diverter (SFD), the flow redirection endoluminal device (FRED), and Surpass. Many questions were raised regarding the long-term complications, the optimal regimen of dual antiplatelet th …
The most widely used devices are the pipeline embolization device (PED), the SILK flow diverter (SFD), the flow redirection endoluminal devi …
Nanotechnology in corneal neovascularization therapy--a review.
Gonzalez L, Loza RJ, Han KY, Sunoqrot S, Cunningham C, Purta P, Drake J, Jain S, Hong S, Chang JH. Gonzalez L, et al. J Ocul Pharmacol Ther. 2013 Mar;29(2):124-34. doi: 10.1089/jop.2012.0158. Epub 2013 Feb 20. J Ocul Pharmacol Ther. 2013. PMID: 23425431 Free PMC article. Review.
These nanomaterials have unique functions at the cellular, atomic, and molecular levels. The term "nanotechnology" was first coined in 1974. Since then, it has evolved dramatically and now consists of distinct and independent scientific fields. ...
These nanomaterials have unique functions at the cellular, atomic, and molecular levels. The term "nanotechnology" was first coined i …
Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke.
Kim JE, Lee RP, Yazigi E, Atta L, Feghali J, Pant A, Jain A, Levitan I, Kim E, Patel K, Kannapadi N, Shah P, Bibic A, Hou Z, Caplan JM, Gonzalez LF, Huang J, Xu R, Fan J, Tyler B, Brem H, Boussiotis VA, Jantzie L, Robinson S, Koehler RC, Lim M, Tamargo RJ, Jackson CM. Kim JE, et al. Among authors: gonzalez lf. Brain Behav Immun. 2024 Feb;116:160-174. doi: 10.1016/j.bbi.2023.12.007. Epub 2023 Dec 7. Brain Behav Immun. 2024. PMID: 38070624 Free article.
Mice receiving sPD-L1 also had higher performance scores short-term, and more closely resembled sham animals on assessments of long-term functional recovery. ...
Mice receiving sPD-L1 also had higher performance scores short-term, and more closely resembled sham animals on assessments of long- …
Long-Term Care Options in Florida: Their Availability by County Demographics.
Gonzalez L. Gonzalez L. J Racial Ethn Health Disparities. 2022 Apr;9(2):698-707. doi: 10.1007/s40615-021-01005-8. Epub 2021 Mar 9. J Racial Ethn Health Disparities. 2022. PMID: 33751483
The present exploratory study uses publicly available data to understand if the geographic availability of long-term care options-skilled nursing, assisted living, home health, and homemaker/companion services-are equally distributed by demographics in Florida. ...The 65 a …
The present exploratory study uses publicly available data to understand if the geographic availability of long-term care options-ski …
155 results